On July 28, 2025, Sinopep's Lianyungang facility achieved another milestone in international regulatory compliance by securing the Certificate of Good Manufacturing Practices (CBPF-GMP) from ANVISA, the Brazilian Health Regulatory Agency and a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This accomplishment follows previous approvals from the U.S. FDA and South Korea's MFDS, underscoring Sinopep's commitment to global quality standards. The audit specifically covered the active pharmaceutical ingredients (APIs) Semaglutide and Liraglutide, and its success will significantly bolster the expansion of these products in international markets.
Letter from ANVISA
Letter Confirming the Granting of a Certificate of Good Manufacturing Practices (CBPF-GMP) by ANVISA, the Brazilian Health Regulatory Agency
About Sinopep
Sinopep (688076.SH) is a leading, technology-driven company specializing in the development and manufacturing of peptides, oligonucleotides, small molecule intermediates, APIs, and drug products. With nearly 15 years of diverse and extensive industry experience, we have consistently delivered high-quality products and services to global pharmaceutical and biotechnology companies, supporting their projects from preclinical development through to commercial production. Sinopep operates three R&D centers and two manufacturing facilities, all of which adhere to rigorous global quality and EHS standards and are approved by the US FDA and EDOM.
